2Cole man RZ, Purohit OP. Osteoclast inhibition for the treatment of bone metastases [J]. Cancer Treat Rev, 1993, 19:79-203.
3Porter AY, Fontanes J. Palliative irradiation for bone metastasis; a new paradigm[J]. Int J Radiat Oncol Biol Phys, 1994, 29:1199.
4Menssen HD, Sakalova A, Fontana A, et al. Zffects of Longterm intravenous ibandronate the rapy on sketetal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma[J]. J Clin Oncol, 2002, 20(9):2353-2359.
5Green JR, Muller K, Jaeggi K A. Preclinical pharmacology of CGP2446 a new , potent, hrterocyclic bisphosphonate compound[J].J Bone Miner Res, 1994,9(5):745～751.
6Pecherstorfer M, Ludwig H, Schlosser K, et al. Administration of the bisphosphonate ibandronate(BM 21.0955) by intravenous bolus injection [J].J Bone Miner Res, 1996,14(5):587～593.
7Lucas LK,Lipman AG.Recent advances in pharmacotherapy for cancer pain management[J].Cancer Pract,2002,10 (suppl 1):S14-20.
8Rizzoli R.Bisphosphonates and reduction of skeletal events in patients with bone metastatic breast cancer[J].Ann Oncol,2004,15(5):700-701.
10Body JJ,Diel IJ,Lichinitser MR,et al.Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases[J].Ann Oncol,2003,14(9):1399-1405.
